Quick Answer
Caris Life Sciences, Inc. reported Total Revenue of $812.03 million for fiscal year 2025.
Caris Life Sciences, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total Revenue | $812.03M +97.0% |
$412.26M +34.7% |
$306.13M | — |
| Revenue (ASC 606) | $812.03M +97.0% |
$412.26M +34.7% |
$306.13M | — |
| Net Income | -$68.09M +75.8% |
-$281.89M +17.4% |
-$341.42M | — |
| Diluted EPS | -$3.22 +69.8% |
-$10.66 +19.5% |
-$13.24 | — |
| Total Assets | $1.13B +227.5% |
$343.73M | — | — |
| Long-Term Debt | $378.82M +18.6% |
$319.44M | — | — |
| Stockholders Equity | $577.31M +123.1% |
-$2.50B -16.5% |
-$2.14B -26.0% |
-$1.70B |
| R&D Expense | $101.58M -10.8% |
$113.92M -2.5% |
$116.88M | — |
| Operating Income | $45.11M +117.5% |
-$257.12M +19.5% |
-$319.55M | — |
| Shares Outstanding | 282.53M +674.0% |
36.50M | — | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $216.83M | +113.4% | +19.5% |
| Revenue (ASC 606) | September 30, 2025 | $216.83M | +113.4% | +19.5% |
| Net Income | September 30, 2025 | $24.32M | +135.9% | +133.9% |
| Diluted EPS | September 30, 2025 | $0.08 | +103.1% | +101.0% |
| Total Assets | September 30, 2025 | $984.57M | — | +3.1% |
| Long-Term Debt | September 30, 2025 | $376.30M | — | +0.7% |
| Stockholders Equity | September 30, 2025 | $478.36M | +119.6% | +5.6% |
| R&D Expense | September 30, 2025 | $21.62M | -21.8% | -13.7% |
| Operating Income | September 30, 2025 | $32.64M | +153.7% | +281.5% |
| Shares Outstanding | September 30, 2025 | 282.10M | — | +0.4% |
- Caris Life Sciences, Inc. reported Total Revenue of $812.03 million for fiscal year 2025.
- Caris Life Sciences, Inc. showed an increase of +97.0% in Total Revenue compared to the prior fiscal year.
- Caris Life Sciences, Inc. reported Revenue (ASC 606) of $812.03 million for fiscal year 2025.
- Caris Life Sciences, Inc. showed an increase of +97.0% in Revenue (ASC 606) compared to the prior fiscal year.
- Caris Life Sciences, Inc. reported Net Income of -$68.09 million for fiscal year 2025.
- Caris Life Sciences, Inc. showed an increase of +75.8% in Net Income compared to the prior fiscal year.
- Caris Life Sciences, Inc. reported Diluted EPS of $3.22 per share (loss) for fiscal year 2025.
- Caris Life Sciences, Inc. showed an increase of +69.8% in Diluted EPS compared to the prior fiscal year.
- Caris Life Sciences, Inc. reported Total Assets of $1.13 billion for fiscal year 2025.
- Caris Life Sciences, Inc. showed an increase of +227.5% in Total Assets compared to the prior fiscal year.
- Caris Life Sciences, Inc. reported Long-Term Debt of $378.82 million for fiscal year 2025.
- Caris Life Sciences, Inc. showed an increase of +18.6% in Long-Term Debt compared to the prior fiscal year.
- Caris Life Sciences, Inc. reported Stockholders Equity of $577.31 million for fiscal year 2025.
- Caris Life Sciences, Inc. showed an increase of +123.1% in Stockholders Equity compared to the prior fiscal year.
- Caris Life Sciences, Inc. reported R&D Expense of $101.58 million for fiscal year 2025.
- Caris Life Sciences, Inc. showed a decrease of -10.8% in R&D Expense compared to the prior fiscal year.
- Caris Life Sciences, Inc. reported Operating Income of $45.11 million for fiscal year 2025.
- Caris Life Sciences, Inc. showed an increase of +117.5% in Operating Income compared to the prior fiscal year.
- Caris Life Sciences, Inc. reported Shares Outstanding of 282.53 million shares for fiscal year 2025.
- Caris Life Sciences, Inc. showed an increase of +674.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: